T. Crockett
Founder bij KalVista Pharmaceuticals Ltd.
Vermogen: 3 M $ op 29-02-2024
Profiel
Founder of KalVista Pharmaceuticals, Inc. and KalVista Pharmaceuticals Ltd., T.
Andrew Crockett currently is Chief Executive Officer & Director at KalVista Pharmaceuticals Ltd.
Mr. Crockett is also on the board of Vantia Ltd.
In the past he held the position of Chief Executive Officer & Director at KalVista Pharmaceuticals, Inc. and Vice President-Business Development at ZARS Pharma, Inc.
He received an MBA from The Wharton School of the University of Pennsylvania, an undergraduate degree from Harvard Business School and an undergraduate degree from the University of Utah.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
20-02-2024 | 211 203 ( 0.51% ) | 3 M $ | 29-02-2024 |
Actieve functies van T. Crockett
Bedrijven | Functie | Begin |
---|---|---|
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Director/Board Member | 01-04-2010 |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Founder | 01-01-2011 |
Eerdere bekende functies van T. Crockett
Bedrijven | Functie | Einde |
---|---|---|
KALVISTA PHARMACEUTICALS, INC. | Founder | 06-03-2024 |
ZARS Pharma, Inc.
ZARS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZARS Pharma, Inc. develops and distributes drugs. It is a specialty pharmaceutical company focused on the development and commercialization of topically administered drugs, primarily for the treatment of pain, using its proprietary drug delivery technologies. The company was founded by Jie Zhang, Theodore H. Stanley, Larry D. Rigby and Michael A. Ashburn in 1996 and is headquartered in Salt Lake City, UT. | Corporate Officer/Principal | - |
Opleiding van T. Crockett
University of Utah | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Harvard Business School | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
KALVISTA PHARMACEUTICALS, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
ZARS Pharma, Inc.
ZARS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZARS Pharma, Inc. develops and distributes drugs. It is a specialty pharmaceutical company focused on the development and commercialization of topically administered drugs, primarily for the treatment of pain, using its proprietary drug delivery technologies. The company was founded by Jie Zhang, Theodore H. Stanley, Larry D. Rigby and Michael A. Ashburn in 1996 and is headquartered in Salt Lake City, UT. | Health Technology |
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Commercial Services |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Health Technology |